Detailed Information on Publication Record
2019
Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry
MIKLÍKOVÁ, Marie, Jiří JARKOVSKÝ, Klára BENEŠOVÁ, Jiří VÍTOVEC, Ales LINHART et. al.Basic information
Original name
Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry
Authors
MIKLÍKOVÁ, Marie (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Jiří VÍTOVEC (203 Czech Republic, belonging to the institution), Ales LINHART (203 Czech Republic), Petr WIDIMSKY (203 Czech Republic), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Kamil ZEMAN (203 Czech Republic), Jan BELOHLAVEK (203 Czech Republic), Filip MALEK, Marián FELŠŐCI (703 Slovakia, belonging to the institution), Jiri KETTNER (203 Czech Republic), Petr OSTADAL (203 Czech Republic), Cestmir CIHALIK (203 Czech Republic), Jiří ŠPÁC (203 Czech Republic, belonging to the institution), Hikmet AL-HITI (203 Czech Republic), Marian FEDORCO (203 Czech Republic), Richard FOJT, Andreas KRUGER (203 Czech Republic), Josef MALEK (203 Czech Republic), Tereza MIKUSOVA (203 Czech Republic), Zdenek MONHART (203 Czech Republic), Stanislava BOHACOVA (203 Czech Republic), Lidka POHLUDKOVA (203 Czech Republic), Filip ROHAC (203 Czech Republic), Jan VACLAVIK (203 Czech Republic), Dagmar VONDRAKOVA (203 Czech Republic), Klaudia VYSKOCILOVA (203 Czech Republic), Miroslav BAMBUCH, Gabriela DOSTALOVA, Stepan HAVRANEK, Ivana SVOBODOVÁ (203 Czech Republic, belonging to the institution), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Roman MIKLIK (guarantor) and Jiří PAŘENICA (203 Czech Republic, belonging to the institution)
Edition
Clinical Cardiology, Hoboken, John Wiley and Sons Inc. 2019, 0160-9289
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30201 Cardiac and Cardiovascular systems
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.248
RIV identification code
RIV/00216224:14110/19:00110765
Organization unit
Faculty of Medicine
UT WoS
000478082600003
Keywords in English
acute heart failure; AHEAD; allopurinol
Tags
International impact, Reviewed
Změněno: 24/9/2019 08:47, Mgr. Tereza Miškechová
Abstract
V originále
Background Hyperuricemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods The prospective acute heart failure registry (AHEAD) was used to select 3160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricemia was defined as UA >= 500 mu moL/L and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricemia, with treated hyperuricemia, and with untreated hyperuricemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricemia, unlike those with hyperuricemia, had a higher left ventricular ejection fraction, a better renal function, and higher hemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. Results In a primary analysis, the patients without hyperuricemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricemia had a similar 5-year survival rate as those with untreated hyperuricemia (42.0% vs 39.7%, P = 0.362) whereas those with treated hyperuricemia had a poorer prognosis (32.4% survival rate, P = 0.006 vs non-hyperuricemia group and P = 0.073 vs untreated group). Conclusion Hyperuricemia was associated with an unfavorable cardiovascular risk profile in HF patients. Treatment with low doses of allopurinol did not improve the prognosis of HF patients.
Links
MUNI/A/1250/2017, interní kód MU |
|